Abstract:To compare the treatment outcomes between young and adult patients with nasopharyngeal carcinoma (NPC) treated with intensity-modulated radiation therapy (IMRT), and to explore if the disease has distinct features in the young age group. We conducted a retrospective case-matched analysis of all patients with non-metastatic NPC ≤20 years treated in our institution between January 2010 and July 2016. Adult patients ≥35 years with NPC treated over the same time period were included and matched at a ratio of 1:1 according to N classification, T classification, treatment modality, year of diagnosis, and gender. Survival outcomes and late treatment-related toxicities were compared between the two groups. Overall 112 young patients with NPC were included, and 112 out of 3105 consecutive patients with NPC aged 35–65 years were matched. The 5-year overall survival (OS), progression-free survival (PFS), locoregional control (LRC) and distant control (DC) of young and adult control cohorts were 89.1% vs. 79.3% (p = 0.03), 80.3% vs. 67.0% (p = 0.02), 96.4% vs. 84.3% (p < 0.01), and 82.9% vs. 82.8% (p = 0.94), respectively. MVA showed that age ≤20 (vs. 35-65) years was the only significant factor predicting for better OS (hazard ratio (HR) = 0.5, 95% confidence interval (CI), 0.3–0.97, p = 0.04). Age ≤20 (vs. 35-65) years and T classification (T4 vs. T1-3) was significant prognostic factors for PFS (HR = 0.6, 95%CI, 0.3–0.96, p = 0.03; HR = 1.8, 95%CI, 1.1–3.0, p = 0.02, respectively). In patients receiving IC+CCRT, long-term survival and disease control rate of patients receiving different IC regimens including TP, TPF, PF and GP, were not significantly different. A trend of higher rate of hypothyroidism (grade 1-2) was observed in the young cohort (67.9% in the young vs. 46.2% in controls, p = 0.08). Young patients with NPC treated with modern multimodality therapy have better survival outcomes. Age ≤20 (vs. 35-65) years was an independent favorable prognostic factor for NPC in the IMRT era. Further prospective studies are needed to establish optimal management for the young population to minimize and manage long-term side-effects without compromising survival.

Treatment of Nasopharyngeal Carcinoma in Unique Scenarios

Nasopharyngeal Carcinoma: Clinical Achievements and Considerations Among Treatment Options

Nasopharyngeal Carcinoma with Particular Characteristics: Case Report.

Future of Radiotherapy in Nasopharyngeal Carcinoma

Early Stage and Locally Advanced Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Going?

Chinese Expert Consensus on Diagnosis and Treatment of Nasopharyngeal Carcinoma: Evidence from Current Practice and Future Perspectives

Combinations of radiotherapy with immunotherapy in nasopharyngeal carcinoma

Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma

A Comprehensive Analysis of Treatment Management and Survival Outcomes in Nasopharyngeal Carcinoma

Management of Nasopharyngeal Carcinoma in Elderly Patients

Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review)

Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes

Advanced Nasopharyngeal Carcinoma: Current and Emerging Treatment Options

Individualized Concurrent Chemotherapy for Patients with Stage III–IVa Nasopharyngeal Carcinoma Receiving Neoadjuvant Chemotherapy Combined with Definitive Intensity-Modulated Radiotherapy

Novel therapy for nasopharyngeal carcinoma--where are we

Nasopharyngeal Carcinoma: Case Presentation and Literature Review of Treatment Innovation with Immunotherapy

Is Nasopharyngeal Carcinoma in Young Patients A Distinct Clinical Entity? A Single-Institution Case Matched Analysis in the Era of Intensity-Modulated Radiotherapy

CACA Guidelines for Holistic Integrative Management of Nasopharyngeal Carcinoma

Treatment and outcomes of nasopharyngeal carcinoma in a unique non-endemic population

Recent advances in early detection of nasopharyngeal carcinoma

Carcinoma of the nasopharynx in young patients: a single institution experience